Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma
Year: 2020
Type: article
Source: Blood
Authors: Michael S. Khodadoust, Tatyana A. Feldman, Dok Hyun Yoon, Costas K. Yannakou, Dejan Radeski, Youn H. Kim, Neha Mehta-Shah, Amit Khot, Ryan A. Wilcox, Won Seog Kim, Steven M. Horwitz, Joseph J. Buggy, Andrew Hotson, Craig M. Hill, Brian Munneke, Suresh Mahabhashyam, Richard A. Miller, James W. Janc, Mehrdad Mobasher
Institutions: Stanford Medicine, Stanford University, Hackensack University Medical Center, Asan Medical Center, University of Ulsan, Epworth Hospital, Sir Charles Gairdner Hospital, Linear Clinical Research, Stanford Cancer Institute, Washington University in St. Louis, Peter MacCallum Cancer Centre, University of Michigan, U-M Rogel Cancer Center, Samsung Medical Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3096193900